Relmada Therapeutics Inc Stock News

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors, IR Sergio Traversa - CEO Maged Shenouda - CFO Conference Call Participants Uy Ear - Mizuho Securities Andrew Tsai - Jefferies Operator Greetings, and welcome to the Relmada Therapeutics, Incorporated Quarter 4 2024 Financial Results Call. At...

Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer  (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome Cash balance of $44.8 million as of December 31 2024 Management hosting co...

CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourt...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 patients, with ~62,000 newly diagnosed patients annually)

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB

Relmada Therapeutics said on Monday it would discontinue the two late-stage studies planned for the development of its depression drug and explore strategic alternatives including a sale.

Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value

Relmada Therapeutics' depression treatment is "unlikely" to meet the main goal of a late-stage trial, it said on Wednesday, citing an independent data monitoring committee's analysis.